- Cat. No.
- A12918
GSK J1
GSK J1 is a potent and selective inhibitor of the H3K27 histone demethylases JMJD3 and UTX
Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Histone demethylase inhibitors block the enzymes that remove methyl groups from lysine residues on histones. Lysine-specific demethylase 1 (LSD1) is a flavin-dependent amine oxidase that demethylates mono- and dimethylated lysine 4 of histone H3 (H3K4). The larger Jumonji C (JmjC) domain family uses iron and 2-oxoglutarate as cofactors, and some members also remove trimethyl marks. SP2509 and GSK2879552 are inhibitors of LSD1 used in chromatin and differentiation studies. GSK J1 targets two demethylases of lysine 27 on histone H3 (H3K27), Jumonji domain-containing protein 3 (JMJD3) and ubiquitously transcribed X-chromosome tetratricopeptide repeat protein (UTX). GSK-J4 is its cell-permeable ester, used for studies in intact cells. JIB-04 acts on several JmjC demethylases, and YUKA1 inhibits lysine-specific demethylase 5A (KDM5A).
GSK J1 is a potent and selective inhibitor of the H3K27 histone demethylases JMJD3 and UTX
GSK J4 is a cell permeable prodrug rapidly hydrolyzed by macrophage esterases to GSK-J1, a potent selective jumonji H3K27 demethylase inhibitor; attenuates lipopolysaccharide (LPS)-induced proinflammatory cytokine production in primary human macrophages (IC50 = 9 uM for the inhibition of TNF, release).
Synonyms: NSC 693627
JIB-04 is a pan-selective Jumonji histone demethylase inhibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.
Synonyms: HCI-2509
SP2509 is a novel histone demethylase LSD1 (KDM1A) antagonist with IC50 of 13 nM; no inhibition on MAO-A and MAO-B.
GSK2879552 is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.
YUKA1 is a potent and cell permeable Lysine demethylase 5A (KDM5A) inhibitor, with an IC50 of 2.66 μM.
Synonyms: Xanthothricin; Toxoflavine; PKF-118-310
Toxoflavin (Xanthothricin) is an antagonist of transcription factor 4 (TCF4)/β-catenin complex, also acts as an inhibitor of KDM4A, with antitumor activity.
Synonyms: Norcoclaurine hydrochloride
Higenamine hydrochloride is a selective inhibitor of LSD1, with an IC50 value of 1.47 μM. This compound exhibits anti-inflammatory and antibacterial properties, and has been shown to attenuate IL-1β-induced apoptosis via the ROS-mediated PI3K/Akt signaling pathway. Additionally, Higenamine hydrochloride protects brain cells from oxygen deprivation and promotes bone formation in osteoporosis through the SMAD2/3 pathway. Its versatile applications make it suitable for research in cancer, inflammation, cardiorenal syndrome, and related diseases.
CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.
Daminozide(DMASA; DIMG; B 995), a plant growth regulator, selectively inhibits the KDM2/7 JmjC subfamily.
LSD1-C76 is a potent and selective Lysine Specific Demethylase-1 (LSD1) inhibitor.
Out of stock
All 3 sizes
Synonyms: KDM4B Inhibitor B3
NCGC00244536 is a potent KDM4B inhibitor with an IC50 of 10 nM.
OG-L002 is a potent and specific LSD1 inhibitor with IC50 of 20 nM, exhibiting 36- and 69-fold selectivity over MAO-B and MAO-A, respectively.
Synonyms: 2-PCPA
Tranylcypromine hydrochloride is a non-selective MAO-A/B inhibitor.
IOX1 is a potent and broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases.
PBIT is a reversible, cell-permeable inhibitor of JARID1 family demethylases (IC50s = 6, 3, 4.9, and 28 uM for JARID1A, JARID1B, JARID1C, and JARID1D, respectively).
ML-324 is a potent JMJD2 demethylase inhibitor with demonstrated antiviral activity.
Synonyms: RG6016
ORY-1001 is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor with IC50 of
CPI 4203 is a selective inhibitor of KDM5 demethylases, structurally related to CPI 455 but ~25-fold less potent (IC50 value 250 nM for inhibition of full length KDM5A).
CPI 455 possesses the target specificity required for an in vitro tool compound for exploring KDM5-dependent disease biology, including drug tolerance.
Synonyms: NCI 51355; NSC 51355
AS8351 is a histone demethylase inhibitor.
2,4-Pyridinedicarboxylic Acid (2,4-PDCA) is an inhibitor of histone lysine-specific demethylases that targets on JMJD2A (KDM4A), KDM4C, KDM4E (IC50, 1.4 μM), KDM5B (IC50, 3 μM), KDM6A and other 2-oxogynases.
Synonyms: TC-E 5002
TC-E 5002, selective histone demethylase KDM2/7 subfamily inhibitor (IC50 values are 0.2, 1.2, 6.8, 55, 83, >100 and >120 uM for KDM7A, KDM7B, KDM2A, KDM5A, KDM4C, KDM6A and KDM4A respectively). Inhibits growth of HeLa and KYSE-150 cancer cells in vitro.
CBB1007 is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).
GSK-LSD1 is a selective inhibitor of lysine-specific demethylase 1 (LSD1). This compound demonstrates significant biological activity by reducing food intake and body weight, while also enhancing insulin sensitivity and glycemic control in mouse models of obesity. Additionally, GSK-LSD1 shows promise in alleviating non-alcoholic fatty liver disease (NAFLD) and inhibiting cytokine release triggered by SARS-CoV-2 in peripheral blood mononuclear cells from COVID-19 patients. Furthermore, GSK-LSD1 has been identified as a potential therapeutic agent for suppressing cancer growth and metastasis.